AMPH

Amphastar Pharmaceuticals' stock has declined by 27.34% in the past six months and approximately 12.90% from May 5, 2025, to May 1, 2026. Q1 2026 earnings missed expectations, with net revenues at $171.2 million and GAAP net income falling to $6.4 million. This was due to lower BAQSIMI® prices, increased competition for legacy products, and higher operating expenses. Glucagon injection sales declined 56% due to competition. Positive contributions came from recently launched products and an 8% increase in U.S. BAQSIMI® sales unit volumes. The company announced a multi-year expansion plan to quadruple its U.S. manufacturing capacity.